Nicotine-mediated cell proliferation and tumor progression in smoking-related cancers

Molecular Cancer Research

Volumn 12, Issue 1, 2014, Pages 14-23

  Schaal, Courtney ^a   Chellappan, Srikumar P ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (METHYLNITROSAMINO) 1 (3 PYRIDYL) 1 BUTANONE; BETA ADRENERGIC RECEPTOR; BUNGAROTOXIN RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; JANUS KINASE; MITOGEN ACTIVATED PROTEIN KINASE; NICOTINE; NICOTINIC RECEPTOR; NITROSONORNICOTINE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; RETINOBLASTOMA PROTEIN; STAT PROTEIN; TOBACCO SMOKE; TRANSCRIPTION FACTOR E2F;

ANGIOGENESIS; APOPTOSIS; CANCER CELL; CANCER GROWTH; CANCER THERAPY; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CELL SURVIVAL; ENZYME ACTIVATION; GENE EXPRESSION; HUMAN; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SMOKING; TUMOR PROMOTION; UPREGULATION;

APOPTOSIS; CELL CYCLE; CELL PROLIFERATION; DISEASE PROGRESSION; DNA DAMAGE; E2F1 TRANSCRIPTION FACTOR; HUMANS; LUNG NEOPLASMS; MAP KINASE SIGNALING SYSTEM; NEOPLASM METASTASIS; NICOTINE; NICOTINIC AGONISTS; RECEPTORS, NICOTINIC; RETINOBLASTOMA PROTEIN; SMOKING; TOBACCO;

EID: 84893098491     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-13-0541     Document Type: Review

References (92)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30.
2. Hecht SS. Tobacco carcinogens, their biomarkers and tobaccoinduced cancer. Nat Rev Cancer 2003;3:733-44.
3. Wakelee HA, Chang ET, Gomez SL, Keegan TH, Feskanich D, Clarke CA, et al. Lung cancer incidence in never smokers. J Clin Oncol 2007;25:472-8.
4. Hecht SS. Tobacco smoke carcinogens and lung cancer. J Natl Cancer Inst 1999;91:1194-210.
5. Phillips DH. Smoking-related DNA and protein adducts in human tissues. Carcinogenesis 2002;23:1979-2004.
6. Furrukh M. Tobacco smoking and lung cancer: perception-changing facts. Sultan Qaboos Univ Med J 2013;13:345-58.
7. Hecht SS. Research opportunities related to establishing standards for tobacco products under the Family Smoking Prevention and Tobacco Control Act. Nicotine Tob Res 2012;14:18-28.
8. Schuller HM, McGavin MD, Orloff M, Riechert A, Porter B. Simultaneous exposure to nicotine and hyperoxia causes tumors in hamsters. Lab Invest 1995;73:448-56.
9. Egleton RD, Brown KC, Dasgupta P. Nicotinic acetylcholine receptors in cancer: multiple roles in proliferation and inhibition of apoptosis. Trends Pharmacol Sci 2008;29:151-8.
10. Dasgupta P, Rizwani W, Pillai S, Kinkade R, Kovacs M, Rastogi S, et al. Nicotine induces cell proliferation, invasion and epithelial-mesenchymal transition in a variety of human cancer cell lines. Int J Cancer 2009;124:36-45.
11. Davis R, Rizwani W, Banerjee S, Kovacs M, Haura E, Coppola D, et al. Nicotine promotes tumor growth and metastasis in mouse models of lung cancer. PLoS ONE 2009;4:e7524.
12. Heeschen C, Jang JJ, Weis M, Pathak A, Kaji S, Hu RS, et al. Nicotine stimulates angiogenesis and promotes tumor growth and atherosclerosis. Nat Med 2001;7:833-9.
13. Sopori M. Effects of cigarette smoke on the immune system. Nat Rev Immunol 2002;2:372-7.
14. SchullerHM. b-Adrenergic signaling, a novel target for cancer therapy? Oncotarget 2010;1:466-9.
15. Carlisle DL, Liu X, Hopkins TM, Swick MC, Dhir R, Siegfried JM. Nicotine activates cell-signaling pathways through muscle-type and neuronal nicotinic acetylcholine receptors in non-small cell lung cancer cells. Pulm Pharmacol Ther 2007;20:629-41.
16. Singh S, Pillai S, Chellappan S. Nicotinic acetylcholine receptor signaling in tumor growth and metastasis. J Oncol 2011;2011:456743.
17. Schuller HM. Is cancer triggered by altered signalling of nicotinic acetylcholine receptors? Nat Rev Cancer 2009;9:195-205.
18. Hecht SS. Biochemistry, biology, and carcinogenicity of tobaccospecific N-nitrosamines. Chem Res Toxicol 1998;11:559-603.
19. Schuller HM. Nitrosamines as nicotinic receptor ligands. Life Sci 2007;80:2274-80.
20. Itier V, Bertrand D. Neuronal nicotinic receptors: from protein structure to function. FEBS Lett 2001;504:118-25.
21. Dasgupta P, Chellappan SP. Nicotine-mediated cell proliferation and angiogenesis: new twists to an old story. Cell Cycle 2006;5:2324-8.
22. Lee CH, Wu CH, Ho YS. From smoking to cancers: novel targets to neuronal nicotinic acetylcholine receptors. J Oncol 2011;2011: 693424.
23. Wu CH, Lee CH, Ho YS. Nicotinic acetylcholine receptor-based blockade: applications of molecular targets for cancer therapy. Clin Cancer Res 2011;17:3533-41.
24. Schuller HM, Orloff M. Tobacco-specific carcinogenic nitrosamines. Ligands for nicotinic acetylcholine receptors in human lung cancer cells. Biochem Pharmacol 1998;55:1377-84.
25. Cattaneo MG, Codignola A, Vicentini LM, Clementi F, Sher E. Nicotine stimulates a serotonergic autocrine loop in human small-cell lung carcinoma. Cancer Res 1993;53:5566-8.
26. Russell MA, Jarvis M, Iyer R, Feyerabend C. Relation of nicotine yield of cigarettes to blood nicotine concentrations in smokers. Br Med J 1980;280:972-6.
27. Armitage AK, Dollery CT, George CF, Houseman TH, Lewis PJ, Turner DM. Absorption and metabolism of nicotine from cigarettes. Br Med J 1975;4:313-6.
28. Trevino JG, Pillai S, Kunigal S, Singh S, Fulp WJ, Centeno BA, et al. Nicotine induces inhibitor of differentiation-1 in a Src-dependent pathway promoting metastasis and chemoresistance in pancreatic adenocarcinoma. Neoplasia 2012;14:1102-14.
29. Momi N, Ponnusamy MP, Kaur S, Rachagani S, Kunigal SS, Chellappan S, et al. Nicotine/cigarette smoke promotes metastasis of pancreatic cancer through a7 nAChR-mediated MUC4 upregulation. Oncogene 2013;32:1384-95.
30. Thorgeirsson TE, Geller F, Sulem P, Rafnar T, Wiste A, Magnusson KP, et al. A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature 2008;452:638-42.
31. Hung RJ, McKay JD, Gaborieau V, Boffetta P, Hashibe M, Zaridze D, et al. A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature 2008;452:633-7.
32. Amos CI, Wu X, Broderick P, Gorlov IP, Gu J, Eisen T, et al. Genomewide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. Nat Genet 2008;40:616-22.
33. Al-Wadei HA, Al-Wadei MH, Schuller HM. Cooperative regulation of non-small cell lung carcinoma by nicotinic and b-adrenergic receptors: a novel target for intervention. PLoS ONE 2012;7:e29915.
34. Pillai S, Rizwani W, Li X, Rawal B, Nair S, Schell MJ, et al. ID1 facilitates the growth and metastasis of non-small cell lung cancer in response to nicotinic acetylcholine receptor and epidermal growth factor receptor signaling. Mol Cell Biol 2011;31:3052-67.
35. Pikor LA, Ramnarine VR, Lam S, Lam WL. Genetic alterations defining NSCLC subtypes and their therapeutic implications. Lung Cancer 2013;82:179-89.
36. Schuller HM. Neurotransmitter receptor-mediated signaling pathways as modulators of carcinogenesis. Prog Exp Tumor Res 2007; 39:45-63.
37. Lam DC, Girard L, Ramirez R, Chau WS, Suen WS, Sheridan S, et al. Expression of nicotinic acetylcholine receptor subunit genes in nonsmall-cell lung cancer reveals differences between smokers and nonsmokers. Cancer Res 2007;67:4638-47.
38. Cattaneo MG, D'Atri F, Vicentini LM. Mechanisms of mitogen-activated protein kinase activation by nicotine in small-cell lung carcinoma cells. Biochem J 1997;328 (Pt 2):499-503.
39. Heusch WL, Maneckjee R. Signalling pathways involved in nicotine regulation of apoptosis of human lung cancer cells. Carcinogenesis 1998;19:551-6.
40. Macklin KD, Maus AD, Pereira EF, Albuquerque EX, Conti-Fine BM. Human vascular endothelial cells express functional nicotinic acetylcholine receptors. J Pharmacol Exp Ther 1998;287:435-9.
41. Maneckjee R, Minna JD. Opioids induce while nicotine suppresses apoptosis in human lung cancer cells. Cell Growth Differ 1994;5: 1033-40.
42. Guo J, Chu M, Abbeyquaye T, Chen CY. Persistent nicotine treatment potentiates amplification of the dihydrofolate reductase gene in rat lung epithelial cells as a consequence of Ras activation. J Biol Chem 2005;280:30422-31.
43. Jull BA, Plummer HK 3rd, Schuller HM. Nicotinic receptor-mediated activation by the tobacco-specific nitrosamine NNK of a Raf-1/MAP kinase pathway, resulting in phosphorylation of c-myc in human small cell lung carcinoma cells and pulmonary neuroendocrine cells. J Cancer Res Clin Oncol 2001;127:707-17.
44. Trombino S, Cesario A, Margaritora S, Granone P, Motta G, Falugi C, et al. a7-Nicotinic acetylcholine receptors affect growth regulation of human mesothelioma cells: role of mitogen-activated protein kinase pathway. Cancer Res 2004;64:135-45.
45. Sharma G, Vijayaraghavan S. Nicotinic receptor signaling in nonexcitable cells. J Neurobiol 2002;53:524-34.
46. Sharma G, Vijayaraghavan S. Nicotinic receptors: role in addiction and other disorders of the brain. Subst Abuse 2008;2008:81.
47. Dasgupta P, Rastogi S, Pillai S, Ordonez-Ercan D, Morris M, Haura E, et al. Nicotine induces cell proliferation by b-arrestin-mediated activation of Src and Rb-Raf-1 pathways. J Clin Invest 2006;116: 2208-17.
48. Kinkade R, Dasgupta P, Carie A, Pernazza D, Carless M, Pillai S, et al. A small molecule disruptor of Rb/Raf-1 interaction inhibits cell proliferation, angiogenesis, and growth of human tumor xenografts in nude mice. Cancer Res 2008;68:3810-8.
49. Trevino JG, Verma M, Singh S, Pillai S, Zhang D, Pernazza D, et al. Selective disruption of Rb-Raf-1 kinase interaction inhibits pancreatic adenocarcinoma growth irrespective of gemcitabine sensitivity. Mol Cancer Ther 2013;12:2722-34.
50. Johnson JL, Pillai S, Pernazza D, Sebti SM, Lawrence NJ, Chellappan SP. Regulation of matrix metalloproteinase genes by E2F transcription factors: Rb-Raf-1 interaction as a novel target for metastatic disease. Cancer Res 2012;72:516-26.
51. Dasgupta P, Rizwani W, Pillai S, Davis R, Banerjee S, Hug K, et al. ARRB1-mediated regulation of E2F target genes in nicotine-induced growth of lung tumors. J Natl Cancer Inst 2011;103:317-33.
52. Rawlings JS, Rosler KM, Harrison DA. The JAK/STAT signaling pathway. J Cell Sci 2004;117:1281-3.
53. Guo J, Kim D, Gao J, Kurtyka C, Chen H, Yu C, et al. IKBKE is induced by STAT3 and tobacco carcinogen and determines chemosensitivity in non-small cell lung cancer. Oncogene 2013;32:151-9.
54. Arredondo J, Chernyavsky AI, Jolkovsky DL, Pinkerton KE, GrandoSA. Receptor-mediated tobacco toxicity: cooperation of the Ras/Raf-1/ MEK1/ERK and JAK-2/STAT-3 pathways downstream of a7 nicotinic receptor in oral keratinocytes. FASEB J 2006;20:2093-101.
55. Chen HZ, Tsai SY, Leone G. Emerging roles of E2Fs in cancer: an exit from cell cycle control. Nat Rev Cancer 2009;9:785-97.
56. Baldi A, De Luca A, Esposito V, Campioni M, Spugnini EP, Citro G. Tumor suppressors and cell-cycle proteins in lung cancer. Patholog Res Int 2011;2011:605042.
57. Dasgupta P, Kinkade R, Joshi B, Decook C, Haura E, Chellappan S. Nicotine inhibits apoptosis induced by chemotherapeutic drugs by up-regulating XIAP and survivin. Proc Natl Acad Sci U S A 2006;103: 6332-7.
58. Chu M, Guo J, Chen CY. Long-term exposure to nicotine, via ras pathway, induces cyclin D1 to stimulate G1 cell cycle transition. J Biol Chem 2005;280:6369-79.
59. Sato T, Abe T, Nakamoto N, Tomaru Y, Koshikiya N, Nojima J, et al. Nicotine induces cell proliferation in association with cyclin D1 upregulation and inhibits cell differentiation in association with p53 regulation in a murine pre-osteoblastic cell line. Biochem Biophys Res Commun 2008;377:126-30.
60. Ho YS, Chen CH, Wang YJ, Pestell RG, Albanese C, Chen RJ, et al. Tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) induces cell proliferation in normal human bronchial epithelial cells through NF-kB activation and cyclin D1 up-regulation. Toxicol Appl Pharmacol 2005;205:133-48.
61. Shin VY, Jin HC, Ng EK, Yu J, Leung WK, Cho CH, et al. Nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone induce cyclooxygenase-2 activity in human gastric cancer cells: involvement of nicotinic acetylcholine receptor (nAChR) and b-adrenergic receptor signaling pathways. Toxicol Appl Pharmacol 2008;233:254-61.
62. Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer 2009;9:153-66.
63. Norton JD. ID helix-loop-helix proteins in cell growth, differentiation and tumorigenesis. J Cell Sci 2000;113 (Pt 22):3897-905.
64. Nishioka T, Yamamoto D, Zhu T, Guo J, Kim SH, Chen CY. Nicotine overrides DNA damage-induced G1/S restriction in lung cells. PLoS ONE 2011;6:e18619.
65. Chen RJ, Ho YS, Guo HR, Wang YJ. Long-term nicotine exposureinduced chemoresistance is mediated by activation of Stat3 and downregulation of ERK1/2 via nAChR and b-adrenoceptors in human bladder cancer cells. Toxicol Sci 2010;115:118-30.
66. Zeng F, Li YC, Chen G, Zhang YK, Wang YK, Zhou SQ, et al. Nicotine inhibits cisplatin-induced apoptosis in NCI-H446 cells. Med Oncol 2012;29:364-73.
67. Egleton RD, Brown KC, Dasgupta P. Angiogenic activity of nicotinic acetylcholine receptors: implications in tobacco-related vascular diseases. Pharmacol Ther 2009;121:205-23.
68. Warren GW, Romano MA, Kudrimoti MR, Randall ME, McGarry RC, Singh AK, et al. Nicotinic modulation of therapeutic response in vitro and in vivo. Int J Cancer 2012;131:2519-27.
69. Cataldo JK, Dubey S, Prochaska JJ. Smoking cessation: an integral part of lung cancer treatment. Oncology 2010;78:289-301.
70. Nordquist LT, Simon GR, Cantor A, Alberts WM, Bepler G. Improved survival in never-smokers vs current smokers with primary adenocarcinoma of the lung. Chest 2004;126:347-51.
71. West KA, Castillo SS, Dennis PA. Activation of the PI3K/AKT pathway and chemotherapeutic resistance. Drug Resist Updat 2002;5:234-48.
72. West KA, Brognard J, Clark AS, Linnoila IR, Yang X, Swain SM, et al. Rapid AKT activation by nicotine and a tobacco carcinogen modulates the phenotype of normal human airway epithelial cells. J Clin Invest 2003;111:81-90.
73. West KA, Linnoila IR, Belinsky SA, Harris CC, Dennis PA. Tobacco carcinogen-induced cellular transformation increases activation of the phosphatidylinositol 30-kinase/AKT pathway in vitro and in vivo. Cancer Res 2004;64:446-51.
74. Nishioka T, Guo J, Yamamoto D, Chen L, Huppi P, Chen CY. Nicotine, through upregulating pro-survival signaling, cooperates with NNK to promote transformation. J Cell Biochem 2010;109:152-61.
75. Tsurutani J, Castillo SS, Brognard J, Granville CA, Zhang C, Gills JJ, et al. Tobacco components stimulate AKT-dependent proliferation and NF-kB-dependent survival in lung cancer cells. Carcinogenesis 2005;26:1182-95.
76. Dan HC, Sun M, Kaneko S, Feldman RI, Nicosia SV, Wang HG, et al. AKT phosphorylation and stabilization of X-linked inhibitor of apoptosis protein (XIAP). J Biol Chem 2004;279:5405-12.
77. Cheng YJ, Jiang HS, Hsu SL, Lin LC, Wu CL, Ghanta VK, et al. XIAPmediated protection of H460 lung cancer cells against cisplatin. Eur J Pharmacol 2010;627:75-84.
78. Ye YN, Liu ES, Shin VY, Wu WK, Luo JC, Cho CH. Nicotine promoted colon cancer growth via epidermal growth factor receptor, c-Src, and 5-lipoxygenase-mediated signal pathway. J Pharmacol Exp Ther 2004;308:66-72.
79. Wen J, Fu JH, Zhang W, Guo M. Lung carcinoma signaling pathways activated by smoking. Chin J Cancer 2011;30:551-8.
80. Samanta D, Gonzalez AL, Nagathihalli N, Ye F, Carbone DP, Datta PK. Smoking attenuates transforming growth factor-b-mediated tumor suppression function through downregulation of Smad3 in lung cancer. Cancer Prev Res 2012;5:453-63.
81. Samanta D, Kaufman J, Carbone DP, Datta PK. Long-term smoking mediated down-regulation of Smad3 induces resistance to carboplatin in non-small cell lung cancer. Neoplasia 2012;14: 644-55.
82. Yu CC, Chang YC. Enhancement of cancer stem-like and epithelialmesenchymal transdifferentiation property in oral epithelial cells with long-term nicotine exposure: reversal by targeting SNAIL. Toxicol Appl Pharmacol 2013;266:459-69.
83. Yu MA, Kiang A, Wang-Rodriguez J, Rahimy E, Haas M, Yu V, et al. Nicotine promotes acquisition of stem cell and epithelial-to-mesenchymal properties in head and neck squamous cell carcinoma. PLoS ONE 2012;7:e51967.
84. Centers for Disease Control and Prevention (U.S.); National Center for Chronic Disease Prevention and Health Promotion (U.S.); Office on Smoking and Health (U.S.). How tobacco smoke causes disease: the biology and behavioral basis for smoking-attributable disease: a report of the surgeon general. Atlanta, GA: U.S. Department of Health and Human Services; 2010.
85. Paleari L, Negri E, Catassi A, Cilli M, Servent D, D'Angelillo R, et al. Inhibition of nonneuronal a7-nicotinic receptor for lung cancer treatment. Am J Respir Crit Care Med 2009;179:1141-50.
86. Alama A, Bruzzo C, Cavalieri Z, Forlani A, Utkin Y, Casciano I, et al. Inhibition of the nicotinic acetylcholine receptors by cobra venom a-neurotoxins: is there a perspective in lung cancer treatment? PLoS ONE 2011;6:e20695.
87. Paleari L, Cesario A, Fini M, Russo P. a7-Nicotinic receptor antagonists at the beginning of a clinical era for NSCLC and mesothelioma? Drug Discov Today 2009;14:822-36.
88. Paleari L, Catassi A, Ciarlo M, Cavalieri Z, Bruzzo C, Servent D, et al. Role of a7-nicotinic acetylcholine receptor in human non-small cell lung cancer proliferation. Cell Prolif 2008;41:936-59.
89. Grozio A, Paleari L, Catassi A, Servent D, Cilli M, Piccardi F, et al. Natural agents targeting the a7-nicotinic-receptor in NSCLC: a promising prospective in anti-cancer drug development. Int J Cancer 2008;122:1911-5.
90. Catassi A, Paleari L, Servent D, Sessa F, Dominioni L, Ognio E, et al. Targeting a7-nicotinic receptor for the treatment of pleural mesothelioma. Eur J Cancer 2008;44:2296-311.
91. Parsons A, Daley A, Begh R, Aveyard P. Influence of smoking cessation after diagnosis of early stage lung cancer on prognosis: systematic review of observational studies with meta-analysis. BMJ 2010;340: b5569.
92. Apelberg BJ, Onicescu G, Avila-Tang E, Samet JM. Estimating the risks and benefits of nicotine replacement therapy for smoking cessation in the United States. Am J Public Health 2010;100: 341-8.